Case report

Cardiogenic shock following acute MI in a young patient with familial hypercholesterolemia, and severe aortic stenosis: A case report

Zeinab Davoodabadi, Zahra Hosseini, Somayeh Norouzi, Hassan Davoodabadi, Reza Sheikh-Sharrafan, Saeed Ghodsi

ARTICLE INFO

Keywords:
- Familial hypercholesterolemia
- Myocardial infarction
- Heart failure
- Aortic stenosis
- Coronary artery disease

ABSTRACT

Background: Familial hypercholesterolemia is a relatively rare disorder with various clinical manifestations including premature coronary artery disease.

Case presentation: A 15-year-old boy presented with acute exacerbation of dyspnea and exertional chest pain with a progressive feature since one month earlier. He had a clustered family history of premature cardiovascular death, hyperlipidemia, and cutaneous lesions in two of his siblings. He presented with acute severe heart failure accompanied with high levels of cardiac troponin and LDL cholesterol. Echocardiography revealed severe LV dysfunction, in concert with valvular and supravalvular Aortic stenosis. He underwent Coronary angiography, which showed involvement of Left main coronary artery and two-vessel disease. The patient was diagnosed with cardiogenic shock secondary to acute non-ST segment elevation myocardial infarction, and phenotype of familial hypercholesterolemia.

Conclusions: Premature malignant atherogenesis in both aortic root and coronary arteries with early presentation of acute myocardial infarction and severe heart failure is an uncommon constellation in early course of the FH, which leads to confined treatment options.

1. Background

Familial Hypercholesterolemia (FH) is a monogenic autosomal dominant disorder characterized as increased low-density lipoprotein cholesterol (LDL-C), early onset coronary artery disease, myocardial infarction, cutaneous manifestations, and premature cardiovascular death. Majority of patients with FH (above 80% of cases) have heterozygous or homozygous mutations involving LDL receptor (LDLR) genes. However, mutations may less frequently occur in the genes encoding apolipoprotein B (ApoB), and proprotein convertase subtilisin/kexin type 9 (PCSK9). These two subtypes comprise approximately 5–10% and <1% of cases, respectively. Untreated cases particularly those with homozygous FH may experience premature atherosclerotic coronary artery disease and subsequent heart failure before the second decade, which is linked to limited survival [1, 2, 3]. Various clinical criteria have been established for diagnosis of FH including the Simon Broome (SB) Register Group [4] in the United Kingdom and the Dutch Lipid Clinic Network (DLCN) [5, 6]. The prevalence of FH phenotype is expected to be 1:500 in prevailing reports [1]. Nevertheless recent molecular and genetic assays demonstrated that true incidence of FH is far higher than assumed (about 1:200) [7]. The presence of Familial hypercholesterolemia is confirmed via having two or more of the following characteristics: 1. Elevated LDL-C levels above 190 mg/dL in the absence of secondary causes of hyperlipidemia such as hypothyroidism, nephrotic syndrome, and hepatic diseases. 2. Cutaneous or tendon xanthomas. 3. History of FH in first-degree relatives or family history of premature CAD. Given this background, a complicated course of FH subtending severe atherosclerotic coronary artery disease, heart failure and valvular disorders leads to limited treatment options and substantial issues in management of the patient.

2. Case presentation

A 15-year-old boy presented with chief complaint of progressive dyspnea on exertion (DOE). Increasing dyspnea with recent exacerbation...
(extension to resting position) was initiated since last year starting as NYHA FC II. The DOE was aggravated since one months before admission, which was appeared in both ordinary activities, and fewer efforts. He felt dyspnea and exertional chest pain radiating to the left arm in less than ordinary activities since 7 days prior to admission in emergency department. The maximum intensity of symptoms including chest pain in conjunction with nausea, vomiting and diaphoresis were experienced within the 24 h of arrival. Initial physical examination at emergency department showed tachycardia (Pulse Rate: 112–125/min), Tachypnea (RR: 18/min), T: 36.8 C, BP: 81/52 (right arm), BP: 78/50 (left arm). Oxygen Saturation without supplemental O2 was 80–85 %.The Jugular Vein appeared slightly distended with mildly increased JVP (approximately 12 cm H2O). Auscultation of the lungs showed diffuse fine crackles heard over two thirds of the pulmonary fields as well as diminished sounds in basilar parts denoting probable pleural effusion and pulmonary edema. A holosystolic murmur with intensity of II/VI in apex radiating to left axilla was detected. Another murmur over left lower sternal border with III–VI amplitude was found. Furthermore, auscultation revealed a II/VI early to mid-diastolic murmur in the aortic area accompanied with a louder mid systolic aortic murmur (III–IV/VI) radiating to right carotid artery. The patient appeared ill with staring eyes and mild respiratory distress. Lid lag, exophthalmos, and corneal arcus in lower border of the eyes were evident. His conjunctival tissue and central mucosa appeared pale. Multiple cutaneous eruptive xanthomas were found especially over extensor sides of the limbs. Swelling due to fibrous deposits were prominent in elbows, knees, Achilles tendons, small joints of both hands and lower limbs. He mentioned a longstanding history mild exertional chest pain during exercise and moderate-intensity activities over childhood that was underappreciated. He mentioned that two siblings showed similar manifestations before premature myocardial infarction and death (including a 9-year-old sister and a 14-year-old brother). His father was examined briefly that resulted in finding corneal arcus, and multiple yellowish nodules over anterior chest and neck. However, the father did not have characteristic xanthomas. The patient has a nephew who is 2-year-old girl with corneal arcus, typical xanthomas and elevated levels of LDL cholesterol. Figure 1(A)–(F) illustrates the corneal arcus and skin xanthomas.

A 12-lead ECG was obtained which showed sinus tachycardia, normal axis, diffuse ST-segment depression (and T wave inversion) accompanied with ST elevation in V1 and AVR leads (Figure 2A). This pattern indicates to a critical stenosis located in left main or proximal of LAD (Left anterior descending). Following a few hours of initial administration of inotropic, vasopressor and anti-angina treatment the ECG showed dynamic changes including declined ST–T deviations and reduced heart rate (Figure 2B). We administered 500 ml normal saline, Norepinephrin 5–10 μg/min and Dopamin 2–4 μg/min infusion intermittently. After about 48 h several intravenous bolus doses furosemide (20 mg) were used with caution. He received supplemental oxygen 5–8 l/min via a facial mask. The patient's laboratory data on admission were as following: WBC: 22,500 (with 86 % Neutrophil, 11 % lymphocytes, mixed: 3.5 %), Hemoglobin: 12.9 gr/dl, platelet: 186,000, C-Reactive Protein (CRP): 2 mg/L, INR: 2.43, magnesium: 1.5 meq/L, Na: 138 meq/L, K: 3.5 meq/L, Urea: 38 mg/dl, Creatinine: 0.9 mg/dl, PH: 7.26, PCO2: 58, PO2: 36.6, HCO3: 25.6, LDL: 546 mg/dl, HDL: 79 mg/dl, Total...
Cholesterol: 634, AST: 42 U/L, ALT: 26 U/L, ALP: 571 U/L, TSH: 0.1 mIU/ml, T4: 13, T3: 94. CK-MB: 37 U/L, Troponin I: 2368 ng/L, BS: 133 mg/dl. PT: 13 s, INR: 1.15, PTT: 31 s. A spiral chest CT scan was performed which illustrated cardiomegaly, moderate bilateral pleural effusion and diffuse congestion. The result of polymerase chain reaction (PCR) test for COVID-19 infection was negative.

Coronary angiography was performed immediately via right femoral artery access, which revealed critical stenosis in ostial segment of left main coronary artery (70–90% narrowing). Proximal of LAD and Left circumflex (LCX) arteries had atherosclerotic plaques with significant (50–70%) stenoses. Proximal portion of LCX showed aneurysmal dilation and mid part of the LCX had a significant 50–70% stenosis. Right coronary artery (RCA) has non-significant atherosclerotic plaques (<25% stenosis). Figure 3A and B depict major lesions detected via coronary angiography and Figure 4 displays some echocardiographic findings.

Transthoracic Echocardiography (TTE) was performed which depicted severe Left ventricular dysfunction with an ejection fraction (LVEF) of 30–35%. Mildly enlarged left atrium and normal right ventricular dimensions as well as preserved function were found. Moderate functional (probably ischemic) mitral regurgitation, moderate tricuspid regurgitation, and thick aortic valve were observed. Systolic pulmonary artery pressure (PAP) was approximately 36 mmHg. Increased gradient across AV was measured with both valvular and supra-valvular stenosis. AV peak and mean gradients were 52 and 30 mmHg, respectively. Moreover, mildly increased diameter of aortic root and ascending portion of thoracic aorta (post-stenotic dilatation) were also observed. There were no intracardiac shunts or congenital drainage variations. Figure 4(A)–(D) illustrates major findings of the TTE. The videos of TTE movies have been presented in supplement file 1.

The patient received Aspirin 80 mg daily, Rosuvastatin 40 mg twice a day, ezetimibe 10 mg daily, intravenous heparin (UFH) 500 U/h, and pantoprazole 20 mg daily. Infusion of furosemide with a 3 mg/h was started and norepinephrine was intermittently administered to maintain peripheral perfusion. The patient was referred to Tehran Heart Center to undergo CABG, AVR, and MV repair. The hemodynamic parameters of the patient were relatively improved and he was prepared for surgery. Unfortunately during the last night prior to operation date, tachycardia, hypotension and heart failure picture gradually exacerbated and he died before transfer to operating room.

3. Discussion

Dutch Lipid Clinic Network Criteria is comprised of five distinct domains including Family History, Clinical History, Clinical Examination, LDL-C Levels, and Genetic analysis [6]. Table 1 describes the Dutch Lipid Clinic criteria for the diagnosis of familial hypercholesterolemia.

Herein the total score of our patient surpass 16 while an overall score over 8 confirms the definite diagnosis of FH. Those subjects with total scores of 6–8, 3–5, and <3 fall into the probable, possible and unlikely

---

Figure 2. A-B. 12-lead ECG strips in Emergency ward and CCU. A. 12-lead ECG strips in Emergency ward. Sinus tachycardia, normal axis, diffuse ST-segment depression and T wave inversion (in AVL, II, AVF, v3-v6, and I) accompanied with ST elevation in V1 and AVR leads. B. 12-lead ECG strip in CCU ward. Normal sinus rhythm, normal axis, diffuse ST-segment depression and T wave inversion (in AVL, II, II, AVF, v3-v6, and I) plus ST- elevation in V1 and AVR leads.

Figure 3. A-B. Main lesions detected via coronary angiography showing left main associated with two-vessel disease. Panel A shows the coronary angiography in RAO 45–Caudal 21°. Panel B shows the coronary angiography in LAO 35–Caudal 30°. In both views, the downward red arrow points to the significant atherosclerotic lesion in proximal portion of the LAD (haziness denotes a fresh thrombotic lesion) while the upward black arrow indicates to critical stenosis of the ostial segment of the left main coronary artery. The arrowhead shows a 50–70% stenosis in mid part of the LCX and the yellow star shows the focal aneurysmal dilation of the proximal segment of the LCX. RAO: Right anterior oblique, LAO: Left anterior oblique, LAD: Left anterior descending, LCX: Left circumflex.
groups for FH. Although we did not perform genetic assay in this case, early onset of the ASCVD and complicated course of the disease accompanied with LDL > 500 mg/dl and multiple fatal events in first-degree relatives robustly support the presence of homozygous FH. A crucial pitfall in this case was lack of timely diagnosis, early family screening and effective primary prevention because of poor socioeconomic status. However, the targets of primary intensive lipid lowering treatment are LDL < 100 mg/dL (for adults) and LDL < 135 mg/dL (for children). Besides, the goal of LDL in established ASCVD is under 70 mg. High-dose statins plus ezetimibe, PCSK9 inhibitors, LDL-apheresis, revascularization and, liver transplantation are available treatment modalities. PCSK9 inhibitors such as alirocumab and evolocumab might be better than oligonucleotide inhibitors ( mipomersen and lomitapide) owing to lower cost and less adverse effects. Invasive strategies including CABG, angioplasty and valve replacement are reserved for symptomatic patients with advanced atherosclerotic disorders. The accelerated atherosclerosis often persists after revascularization despite lipid lowering therapy. However, strict LDL decline is mandatory in order to slow down the recurrence of lesions.

Delayed diagnosis and treatment of Familial hypercholesterolemia in children in addition to optimal revascularization approach continue to be controversial problems. Appropriate timing of intervention, CABG with or without valve replacement (repair), PCI with DES vs. bio-absorbable stents, and management of cardiogenic shock remain unclear in this setting [8]. However, the unique feature of our patient was the presence of combined severe left main (and two-vessel disease) coronary lesions plus aortic stenosis (valvular and supravalvular), mitral regurgitation, and heart failure presenting with cardiogenic shock. Left main angioplasty with DES was not feasible in this case due to low expertise as well as incomplete revascularization (remained AS, and mid part LCX lesion), poor angle of LM-LCX, and high likelihood of stent thrombosis or in-stent restenosis. Besides, the proximal portion of LCX was also aneurysmal increasing the probability of poor stent apposition and thrombosis. Furthermore, small diameter of DES in pediatric patients and normal growth of the coronary arteries may lead to critical size mismatch and restenosis. Left main coronary artery may have up to four-fold increase in diameter in older ages [8]. On the other hand, difficult anastomoses of grafts to small arteries, lower patency of grafts in children, underdeveloped LIMA, systemic and cerebral hypoperfusion in the presence of two-level severe AS complicate the CABG. Herein, concomitant aortic stenosis and moderate aortic regurgitation restricted the use of mechanical circulatory support devices such as intra-aortic balloon pump (IABP). Moreover, insertion of an Impella might be difficult through a narrow outflow tract [8, 9, 10]. Extra-corporeal membrane oxygenation (ECMO) was not available in our center. There are also several challenges regarding anesthesia in this patient. Anesthesia induction with stable haemodynamics and sufficient depth are mandatory using central venous pressures (CVP), pulse oximetry (SpO2) and end-tidal carbon dioxide (EtCO2). Avoiding both bradycardia, and tachycardia as well as maintaining the preload and afterload are also essential. Occurrence of systemic hypotension compromises coronary perfusion pressure. Mitral regurgitation is also a challenging factor in this case which might be increased via slow heart rates in concert with reduction of forward flow and LV distension [11]. Supra valvular aortic stenosis due to progressive

Figure 4. Transthoracic Echocardiographic images. (A) Parasternal long axis (PLAX) view showing atherosclerotic plaques in aortic root leading to valvular and supravalvular stenosis (red arrowheads). (B) PLAX view with turbulence (stenosis) of color Doppler in two distinct levels (Aortic valve with red arrow and ascending aorta with black arrow). (C) Apical four chamber view showing at least moderate mitral regurgitation (MR with yellow arrowhead). (D) Suprasternal view with pulsed wave Doppler showing increased gradient in supravalvular area.
Table 1. Dutch Lipid Clinic Network diagnostic criteria for Familial Hypercholesterolemia.

| Domains of the criteria | Scores |
|-------------------------|--------|
| Patient's past history and family history | |
| 1. Premature atherosclerotic coronary artery disease in first-degree relatives (males <55 years, females <60 years) | 1 |
| OR | |
| 2. Age and sex adjusted LDL-C > 95th percentile in first-degree relatives | 1 |
| OR | |
| 3. Family history of tendon xanthoma and/or corneal arcus | 2 |
| OR | |
| 4. Age and sex adjusted LDL-C > 95th percentile in patients under 18 years | 2 |
| 2. The category of clinical history: 1. Premature coronary artery disease in the patient | 2 |
| 2. Premature peripheral vascular or cerebral disease in the patient | 1 |
| The category of physical examination: | |
| 1. Tendon Xanthomata | 6 |
| 2. Corneal arcus at age under 45 years. | 4 |
| The category of LDL concentration: | |
| 1. >330 mg/dL (8.5 mmol/L) | 8 |
| 2. 250-329 mg/dL (6.5-8.5 mmol/L) | 5 |
| 3. 190-249 mg/dL (4.9-6.4 mmol/L) | 3 |
| 4. 155-189 mg/dL (4.0-4.9 mmol/L) | 1 |
| DNA analysis | |
| Detection of functional mutant alleles in genes pertaining to LDLR, APOB and PCSK9 | 8 |

Diagnosis

| Diagnosis | |
|-----------|--------|
| Definite FH | >8 |
| Probable FH | 6–7 |
| Possible FH | 3–5 |
| Unlikely FH | <3 |

Atherosclerosis at the aortic root is frequently seen in FH (nearly 41%). However, simultaneous valvular and supravalvular stenosis is uncommon. This phenotype per se may lead to sudden cardiac death in about 32% of cases [12].

4. Conclusions

Familial hypercholesterolemia is a rare autosomal dominant inherited disorder leading to premature ASCVD and death. Combination of cardiogenic shock in the setting of multiple valvular disease, severe coronary lesions including ostial of left main coronary artery, and severe cardiomyopathy is extremely rare and fatal. The optimal approach for revascularization, timing of interventions, and intensive care modalities are unknown in these patients and heart team approach is recommended for decision making.

Declarations

Author contribution statement

All authors listed have significantly contributed to the investigation, development and writing of this article.

Funding statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data availability statement

No data was used for the research described in the article.

Declaration of interest’s statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

References

[1] D. Marks, M. Thorogood, H.A. Neil, S.E. Humphries, A review on the diagnosis, natural history, and treatment of familial hypercholesterolemia, Atherosclerosis 168 (2003) 1–14.
[2] M. Cuchel, E. Bruckert, H.N. Ginsberg, F.J. Raal, R.D. Santos, R.A. Hegele, et al., Homozygous familial hypercholesterolemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolemia of the European Atherosclerosis Society, Eur. Heart J. 35 (2014) 2146–2157.
[3] J.P. Strong, G.T. Malcom, C.A. McMahan, R.E. Tracy, W.P. Newman 3rd, E.E. Herderick, et al., Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study, JAMA 281 (1999) 727–735.
[4] Scientific Steering Committee on behalf of the Simon Broomes Register Group, Risk of fatal coronary heart disease in familial hypercholesterolemia, BMJ 303 (1991) 893–896.
[5] B.C. Nordestgaard, M.J. Chapman, S.E. Humphries, H.N. Ginsberg, L. Masana, O.S. Descamps, et al., Familial hypercholesterolemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society, Eur. Heart J. 34 (2013) 3478–3490.
[6] M.P. McGowan, S.H. Hosseini Dekhordi, P.M. Moriarty, et al., Diagnosis and treatment of heterozygous familial hypercholesterolemia, J. Am. Heart Assoc. 8 (2019), e01225.
[7] M. Harada-Shiba, H. Arai, Y. Ishigaki, et al., Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017, J. Atherosclerosis Thromb. 25 (2018) 751–770.
[8] L. Ungar, D. Sanders, B. Becerra, A. Barzeghian, Percutaneous coronary intervention in familial hypercholesterolemia is understudied, Front. Cardiovasc. Med. 5 (2018) 116.
[9] A. Amaa, T. Sarioglu, Y. Yalcinbas, E. Erek, R. Turkoz, A. Oktay, A. Saygiil, D. Altun, A. Sarigol, Coronary artery bypass grafting in children, J. Card. Surg. 33 (1) (2018) 29–34.
[10] J.M. Santana, A.A. Dalia, M. Newton, D.V. Pinazo, S. Eapen, M. Kawabori, J. Ortoleva, Mechanical circulatory support options in patients with aortic valve pathology, J. Cardiothorac. Vasc. Anesth. (2022). S1053-0770(22)00269-5.
[11] Abhijit Paul, Sucharita Das, Valvular heart disease and anaesthesia, Indian J. Anaesth.: September 61 (9) (2017) 721–727.
[12] R. Zhang, J. Xie, J. Zhou, L. Xu, Y. Pan, Y. Qu, R. Li, M. Chong, L. Song, W. Wen, Y. Wu, J. Li, L. Wang, Y. Yang, Supravalvular aortic stenosis and the risk of premature death among patients with homozygous familial hypercholesterolemia, Am. J. Cardiol. 145 (2021) 58–63.